Perspective Therapeutics (CATX) Payables (2011 - 2026)

Perspective Therapeutics (CATX) has 16 years of Payables data on file, last reported at $26.5 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 202.05% year-over-year to $26.5 million; the trailing twelve-month figure through Mar 2026 stood at $26.5 million (up 202.05% YoY), and the FY2025 full-year result was $20.6 million, up 97.85% from the prior year.
• Payables grew to $26.5 million in Q1 2026, from $20.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $26.5 million in Q1 2026 to a low of $769000.0 in Q1 2022.
• A 5-year average of $8.6 million and a median of $6.2 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables soared 458.47% in 2024 and plunged 39.61% in 2025, its largest moves.
• Tracing CATX's Payables over 5 years: stood at $1.5 million in 2022, then surged by 351.52% to $7.0 million in 2023, then surged by 49.4% to $10.4 million in 2024, then soared by 97.85% to $20.6 million in 2025, then advanced by 29.05% to $26.5 million in 2026.
• Business Quant data shows CATX's Payables at $26.5 million in Q1 2026, $20.6 million in Q4 2025, and $13.2 million in Q3 2025.